Treatment of Intractable Rheumatoid Arthritis with Total Lymphoid Irradiation

B. L. Kotzin, S. Strober, E. G. Engleman, A. Calin, R. T. Hoppe, G. S. Kansas, C. P. Terrell, H. S. Kaplan

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Eleven patients with intractable rheumatoid arthritis were treated with total lymphoid irradiation (total dose, 2000 rad) in an uncontrolled feasibility study, as an alternative to long-term therapy with cytotoxic drugs such as cyclophosphamide and azathioprine. During a follow-up period of five to 18 months after total lymphoid irradiation, there was a profound and sustained suppression of the absolute lymphocyte count and in vitro lymphocyte function, as well as an increase in the ratio of Leu-2 (suppressor/cytotoxic) to Leu-3 (helper) T cells In the blood. Persistent circulating suppressor cells of the mixed leukocyte response and of pokeweed mitogen-induced immunoglobulin secretion developed in most patients. In nine of the 11 patients, these changes in immune status were associated with relief of joint tenderness and swelling and with improvement in function scores. Maximum improvement occurred approximately six months after irradiation and continued for the remainder of the observation period. Few severe or chronic side effects were associated with the radiotherapy. (N Engl J Med. 1981; 305:969–76.). TOTAL lymphoid irradiation has been used to treat Hodgkin#x0027; s disease and non-Hodgkin lymphomas for the past 20 years.1 Few serious side effects have been observed in long-term follow-up studies. There has been no measurable increase in the risk of leukemia or other neoplasms in several hundred patients with Hodgkin#x0027; s disease who were given total lymphoid irradiation without chemotherapy and who had no evidence of recurrence of disease for up to 10 years.2 , 3 The incidence of severe viral or bacterial infection or of radiation-induced pneumonitis or enteritis requiring hospitalization is less than 1 per cent.1 Nevertheless, we have shown that cell-mediated. . .

Original languageEnglish (US)
Pages (from-to)969-976
Number of pages8
JournalNew England Journal of Medicine
Volume305
Issue number17
DOIs
StatePublished - Oct 22 1981

Fingerprint

Lymphatic Irradiation
Rheumatoid Arthritis
Hodgkin Disease
Radiation Pneumonitis
Pokeweed Mitogens
Enteritis
Azathioprine
Lymphocyte Count
Feasibility Studies
Virus Diseases
Therapeutics
Helper-Inducer T-Lymphocytes
Bacterial Infections
Non-Hodgkin's Lymphoma
Cyclophosphamide
Immunoglobulins
Leukemia
Hospitalization
Leukocytes
Radiotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kotzin, B. L., Strober, S., Engleman, E. G., Calin, A., Hoppe, R. T., Kansas, G. S., ... Kaplan, H. S. (1981). Treatment of Intractable Rheumatoid Arthritis with Total Lymphoid Irradiation. New England Journal of Medicine, 305(17), 969-976. https://doi.org/10.1056/NEJM198110223051702
Kotzin, B. L. ; Strober, S. ; Engleman, E. G. ; Calin, A. ; Hoppe, R. T. ; Kansas, G. S. ; Terrell, C. P. ; Kaplan, H. S. / Treatment of Intractable Rheumatoid Arthritis with Total Lymphoid Irradiation. In: New England Journal of Medicine. 1981 ; Vol. 305, No. 17. pp. 969-976.
@article{b87b5df4b687475f9d213bf945e5a710,
title = "Treatment of Intractable Rheumatoid Arthritis with Total Lymphoid Irradiation",
abstract = "Eleven patients with intractable rheumatoid arthritis were treated with total lymphoid irradiation (total dose, 2000 rad) in an uncontrolled feasibility study, as an alternative to long-term therapy with cytotoxic drugs such as cyclophosphamide and azathioprine. During a follow-up period of five to 18 months after total lymphoid irradiation, there was a profound and sustained suppression of the absolute lymphocyte count and in vitro lymphocyte function, as well as an increase in the ratio of Leu-2 (suppressor/cytotoxic) to Leu-3 (helper) T cells In the blood. Persistent circulating suppressor cells of the mixed leukocyte response and of pokeweed mitogen-induced immunoglobulin secretion developed in most patients. In nine of the 11 patients, these changes in immune status were associated with relief of joint tenderness and swelling and with improvement in function scores. Maximum improvement occurred approximately six months after irradiation and continued for the remainder of the observation period. Few severe or chronic side effects were associated with the radiotherapy. (N Engl J Med. 1981; 305:969–76.). TOTAL lymphoid irradiation has been used to treat Hodgkin#x0027; s disease and non-Hodgkin lymphomas for the past 20 years.1 Few serious side effects have been observed in long-term follow-up studies. There has been no measurable increase in the risk of leukemia or other neoplasms in several hundred patients with Hodgkin#x0027; s disease who were given total lymphoid irradiation without chemotherapy and who had no evidence of recurrence of disease for up to 10 years.2 , 3 The incidence of severe viral or bacterial infection or of radiation-induced pneumonitis or enteritis requiring hospitalization is less than 1 per cent.1 Nevertheless, we have shown that cell-mediated. . .",
author = "Kotzin, {B. L.} and S. Strober and Engleman, {E. G.} and A. Calin and Hoppe, {R. T.} and Kansas, {G. S.} and Terrell, {C. P.} and Kaplan, {H. S.}",
year = "1981",
month = "10",
day = "22",
doi = "10.1056/NEJM198110223051702",
language = "English (US)",
volume = "305",
pages = "969--976",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "17",

}

Kotzin, BL, Strober, S, Engleman, EG, Calin, A, Hoppe, RT, Kansas, GS, Terrell, CP & Kaplan, HS 1981, 'Treatment of Intractable Rheumatoid Arthritis with Total Lymphoid Irradiation', New England Journal of Medicine, vol. 305, no. 17, pp. 969-976. https://doi.org/10.1056/NEJM198110223051702

Treatment of Intractable Rheumatoid Arthritis with Total Lymphoid Irradiation. / Kotzin, B. L.; Strober, S.; Engleman, E. G.; Calin, A.; Hoppe, R. T.; Kansas, G. S.; Terrell, C. P.; Kaplan, H. S.

In: New England Journal of Medicine, Vol. 305, No. 17, 22.10.1981, p. 969-976.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of Intractable Rheumatoid Arthritis with Total Lymphoid Irradiation

AU - Kotzin, B. L.

AU - Strober, S.

AU - Engleman, E. G.

AU - Calin, A.

AU - Hoppe, R. T.

AU - Kansas, G. S.

AU - Terrell, C. P.

AU - Kaplan, H. S.

PY - 1981/10/22

Y1 - 1981/10/22

N2 - Eleven patients with intractable rheumatoid arthritis were treated with total lymphoid irradiation (total dose, 2000 rad) in an uncontrolled feasibility study, as an alternative to long-term therapy with cytotoxic drugs such as cyclophosphamide and azathioprine. During a follow-up period of five to 18 months after total lymphoid irradiation, there was a profound and sustained suppression of the absolute lymphocyte count and in vitro lymphocyte function, as well as an increase in the ratio of Leu-2 (suppressor/cytotoxic) to Leu-3 (helper) T cells In the blood. Persistent circulating suppressor cells of the mixed leukocyte response and of pokeweed mitogen-induced immunoglobulin secretion developed in most patients. In nine of the 11 patients, these changes in immune status were associated with relief of joint tenderness and swelling and with improvement in function scores. Maximum improvement occurred approximately six months after irradiation and continued for the remainder of the observation period. Few severe or chronic side effects were associated with the radiotherapy. (N Engl J Med. 1981; 305:969–76.). TOTAL lymphoid irradiation has been used to treat Hodgkin#x0027; s disease and non-Hodgkin lymphomas for the past 20 years.1 Few serious side effects have been observed in long-term follow-up studies. There has been no measurable increase in the risk of leukemia or other neoplasms in several hundred patients with Hodgkin#x0027; s disease who were given total lymphoid irradiation without chemotherapy and who had no evidence of recurrence of disease for up to 10 years.2 , 3 The incidence of severe viral or bacterial infection or of radiation-induced pneumonitis or enteritis requiring hospitalization is less than 1 per cent.1 Nevertheless, we have shown that cell-mediated. . .

AB - Eleven patients with intractable rheumatoid arthritis were treated with total lymphoid irradiation (total dose, 2000 rad) in an uncontrolled feasibility study, as an alternative to long-term therapy with cytotoxic drugs such as cyclophosphamide and azathioprine. During a follow-up period of five to 18 months after total lymphoid irradiation, there was a profound and sustained suppression of the absolute lymphocyte count and in vitro lymphocyte function, as well as an increase in the ratio of Leu-2 (suppressor/cytotoxic) to Leu-3 (helper) T cells In the blood. Persistent circulating suppressor cells of the mixed leukocyte response and of pokeweed mitogen-induced immunoglobulin secretion developed in most patients. In nine of the 11 patients, these changes in immune status were associated with relief of joint tenderness and swelling and with improvement in function scores. Maximum improvement occurred approximately six months after irradiation and continued for the remainder of the observation period. Few severe or chronic side effects were associated with the radiotherapy. (N Engl J Med. 1981; 305:969–76.). TOTAL lymphoid irradiation has been used to treat Hodgkin#x0027; s disease and non-Hodgkin lymphomas for the past 20 years.1 Few serious side effects have been observed in long-term follow-up studies. There has been no measurable increase in the risk of leukemia or other neoplasms in several hundred patients with Hodgkin#x0027; s disease who were given total lymphoid irradiation without chemotherapy and who had no evidence of recurrence of disease for up to 10 years.2 , 3 The incidence of severe viral or bacterial infection or of radiation-induced pneumonitis or enteritis requiring hospitalization is less than 1 per cent.1 Nevertheless, we have shown that cell-mediated. . .

UR - http://www.scopus.com/inward/record.url?scp=0019455461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019455461&partnerID=8YFLogxK

U2 - 10.1056/NEJM198110223051702

DO - 10.1056/NEJM198110223051702

M3 - Article

C2 - 6456414

AN - SCOPUS:0019455461

VL - 305

SP - 969

EP - 976

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 17

ER -